CVE:NTB

12942 (NTB.V) Stock Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume31,049 shs
Average Volume315,395 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive NTB News and Ratings via Email

Sign-up to receive the latest news and ratings for 12942 (NTB.V) and its competitors with MarketBeat's FREE daily newsletter.


About 12942 (NTB.V)

Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company's products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).

Headlines

Global Krill Oil Industry
Global Krill Oil Industry
October 2, 2020 |  benzinga.com
Edited Transcript of NTB.TO earnings conference call or presentation 10-Jun-20 8:30pm GMT
Edited Transcript of NTB.TO earnings conference call or presentation 10-Jun-20 8:30pm GMT
June 11, 2020 |  finance.yahoo.com
Neptune Receives Confirmation of Readiness Letter from Health Canada
Neptune Receives Confirmation of Readiness Letter from Health Canada
May 26, 2020 |  www.bloomberg.com
Europe Nutritional Lipid Market to 2027 - Regional Analysis and Forecasts by Type ; Application ; Source ; Form, and Country
Europe Nutritional Lipid Market to 2027 - Regional Analysis and Forecasts by Type ; Application ; Source ; Form, and Country
April 23, 2020 |  finance.yahoo.com
North America Nutritional Lipid Market to 2027 - Regional Analysis and Forecasts by Type ; Application ; Source ; Form, and Country
North America Nutritional Lipid Market to 2027 - Regional Analysis and Forecasts by Type ; Application ; Source ; Form, and Country
April 22, 2020 |  uk.finance.yahoo.com
Neptune Files Two Patent Applications for Innovative Cannabis Extraction Processes
Neptune Files Two Patent Applications for Innovative Cannabis Extraction Processes
March 7, 2020 |  www.bloomberg.com
Edited Transcript of NTB.TO earnings conference call or presentation 13-Feb-20 1:30pm GMT
Edited Transcript of NTB.TO earnings conference call or presentation 13-Feb-20 1:30pm GMT
February 13, 2020 |  finance.yahoo.com
Global Animal Health Partnering Terms & Agreements 2014-2019: Deal Trends, Key Players, Top Deal Values, Deal Financials
Global Animal Health Partnering Terms & Agreements 2014-2019: Deal Trends, Key Players, Top Deal Values, Deal Financials
February 12, 2020 |  www.globenewswire.com
Neptune Announces Fourth Quarter and Year-end Results
Neptune Announces Fourth Quarter and Year-end Results
February 12, 2020 |  www.bloomberg.com
Edited Transcript of NTB.TO earnings conference call or presentation 11-Nov-19 1:30pm GMT
Edited Transcript of NTB.TO earnings conference call or presentation 11-Nov-19 1:30pm GMT
November 15, 2019 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.68 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











12942 (NTB.V) (CVE:NTB) Frequently Asked Questions

What stocks does MarketBeat like better than 12942 (NTB.V)?

Wall Street analysts have given 12942 (NTB.V) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 12942 (NTB.V) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were 12942 (NTB.V)'s earnings last quarter?

12942 (NTB.V) (CVE:NTB) released its earnings results on Tuesday, July, 15th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $3.69 million during the quarter, compared to analysts' expectations of $7.31 million.
View 12942 (NTB.V)'s earnings history.

Is 12942 (NTB.V) a good dividend stock?

12942 (NTB.V) pays an annual dividend of C$1.52 per share and currently has a dividend yield of 0.00%.
View 12942 (NTB.V)'s dividend history.

Who are 12942 (NTB.V)'s key executives?

12942 (NTB.V)'s management team includes the following people:
  • John Moretz, Chairman of the Board
  • James Stuart Hamilton, President, Chief Executive Officer, Director
  • Mario Paradis, Chief Financial Officer
  • Michel Timperio, Senior Vice President of Sales - Global Sales
  • Pierre Lemieux Ph.D., Chief Operating Officer of Acasti
  • Jean-Daniel Belanger, Corporate Secretary and Director - Corporate Affairs
  • Harlan W. Waksal M.D., Director (Age 61)
  • Valier Boivin, Independent Director
  • Ronald Denis, Independent Director
  • Adrian Taylor Montgomery, Independent Director

What other stocks do shareholders of 12942 (NTB.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 12942 (NTB.V) investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).

What is 12942 (NTB.V)'s stock symbol?

12942 (NTB.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NTB."

How do I buy shares of 12942 (NTB.V)?

Shares of NTB and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is 12942 (NTB.V)'s official website?

The official website for 12942 (NTB.V) is neptunekrilloil.com.

Where are 12942 (NTB.V)'s headquarters?

12942 (NTB.V) is headquartered at 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada.

How can I contact 12942 (NTB.V)?

12942 (NTB.V)'s mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The biotechnology company can be reached via phone at +1-450-6872262.


This page was last updated on 7/27/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.